SCHEMBL8629038

SCHEMBL8629038

Cc1cnc2c(c1)CC(=O)N2C

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP11B2 P19099 3/20 0.36
TRIM24 O15164 1/20 0.35
BMPR1B O00238 6/20 0.35
BMPR1A P36894 6/20 0.35
ACVRL1 P37023 6/20 0.35
ACVR1 Q04771 6/20 0.35
TGFBR1 P36897 3/20 0.33
SRD5A1 P18405 1/20 0.33
IDH1 O75874 1/20 0.32
KMT2A Q03164 3/20 0.32
MEN1 O00255 2/20 0.32
GAA P10253 2/20 0.32
CASP6 P55212 1/20 0.32
HTR1A P08908 1/20 0.32
DRD2 P14416 1/20 0.32
HTR2A P28223 1/20 0.32
CYP11B1 P15538 1/20 0.31
PDE5A O76074 1/20 0.31
TLR9 Q9NR96 1/20 0.31
CCR1 P32246 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL46315 0.84 CYP11B2 (0.50) CYP11B2BMPR1BBMPR1AACVRL1ACVR1
SCHEMBL26621580 0.81 CYP11B2 (0.36) CYP11B2TRIM24BMPR1BBMPR1AACVRL1
SCHEMBL30661603 0.81 CYP11B2 (0.36) CYP11B2TRIM24BMPR1BBMPR1AACVRL1
SCHEMBL8137963 0.81 HSD17B10 (0.41) CYP11B2TRIM24BMPR1BBMPR1AACVRL1
SCHEMBL27071821 0.78 ACVRL1 (0.38) CYP11B2BMPR1BBMPR1AACVRL1ACVR1
SCHEMBL11922155 0.78 KDM4E (0.36) CYP11B2TRIM24BMPR1BBMPR1AACVRL1
SCHEMBL8627202 0.77 ALDH1A1 (0.34) CYP11B2TRIM24BMPR1BBMPR1AACVRL1
SCHEMBL8630032 0.77 MAPT (0.38) CYP11B2BMPR1BBMPR1AACVRL1ACVR1
SCHEMBL18422666 0.77 LMNA (0.35) CYP11B2BMPR1BBMPR1AACVRL1ACVR1
SCHEMBL46312 0.75 IDH1 (0.35) IDH1KMT2AMEN1HTR1ADRD2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023212147-A1 HETEROCYCLIC COMPOUNDS AS MODULATORS OF BCL6 AS LIGAND DIRECTED DEGRADERS CELGENE CORPORATION (US) 2023-11-02 WO disclosed
EP-3750880-B1 PYRAZINE-2(1H)-KETONE COMPOUND ACTING AS FGFR INHIBITOR ZHANGZHOU PIEN TZE HUANG PHARM (CN) 2022-12-21 EP disclosed
WO-2022174253-A1 HPK1 ANTAGONISTS AND USES THEREOF Nimbus Saturn, Inc. (US) 2022-08-18 WO disclosed
US-11286248-B2 Pyrazine-2(1H)-ketone compound acting as FGFR inhibitor ZHANGZHOU PIEN TZE HUANG PHARMACEUTICAL CO., LTD. (CN) 2022-03-29 US disclosed
US-20210040070-A1 PYRAZINE-2(1H)-KETONE COMPOUND ACTING AS FGFR INHIBITOR ZHANGZHOU PIEN TZE HUANG PHARMACEUTICAL CO., LTD. (CN) 2021-02-11 US disclosed
EP-3750880-A1 PYRAZINE-2(1H)-KETONE COMPOUND ACTING AS FGFR INHIBITOR Zhangzhou Pien Tze Huang Pharmaceutical Co., Ltd (CN) 2020-12-16 EP disclosed
WO-2019154364-A1 PYRAZINE-2(1H)-KETONE COMPOUND ACTING AS FGFR INHIBITOR 南京明德新药研发有限公司 2019-08-15 WO disclosed
US-9120792-B2 Fused heterocyclic compound SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2015-09-01 US disclosed
US-20150094329-A1 FUSED HETEROCYCLIC COMPOUND SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2015-04-02 US disclosed
US-20110201629-A1 CYCLOHEXYL AMIDE DERIVATIVES AS CRF RECEPTOR ANTAGONISTS NOVARTIS AG (CH) 2011-08-18 US disclosed
US-5767128-A ANALGESICS ADIR ET COMPAGNIE (FR) 1998-06-16 US disclosed
US-5618819-A ANALGESICS ADIR ET COMPAGNIE (FR) 1997-04-08 US disclosed
EP-0691339-A1 Amine derivatives of 1,3-dihydro-2H-pyrrolo(2,3-b)pyridin-2-ones and oxazolo(4,5-b)pyridin-2(3H)-ones, their process of preparation and pharmaceutical compositions containing them ADIR ET COMPAGNIE (FR) 1996-01-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210040070-A1 PYRAZINE-2(1H)-KETONE COMPOUND ACTING AS FGFR INHIBITOR FGFR1, FGFR2, FGFR3 CYP11B2 164/4885TRIM24 3555/4885BMPR1B 950/4885
US-20110201629-A1 CYCLOHEXYL AMIDE DERIVATIVES AS CRF RECEPTOR ANTAGONISTS CRHR1, CRHR2, CRH CYP11B2 838/4885TRIM24 3148/4885BMPR1B 1063/4885
US-11286248-B2 Pyrazine-2(1H)-ketone compound acting as FGFR inhibitor FGFR1, FGFR2, FGFR3 CYP11B2 164/4885TRIM24 3555/4885BMPR1B 950/4885
US-20150094329-A1 FUSED HETEROCYCLIC COMPOUND CYC1, H1-0, H1-3 CYP11B2 67/4885TRIM24 4476/4885BMPR1B 542/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.